Sangamo Therapeutics Inc.
09/11/2025 | Press release | Distributed by Public on 09/11/2025 15:01
Management Change/Compensation (Form 8-K)
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On September 9, 2025, Prathyusha Duraibabu, notified Sangamo Therapeutics, Inc. (the "Company") of her decision to resign from her position as Chief Financial Officer of the Company, effective October 1, 2025 (the "Transition Date"), in order to assume a senior leadership role with a privately-held artificial intelligence company. Ms. Duraibabu's resignation is not due to any disagreement relating to the Company's operations, financial statements, internal controls, auditors, policies or practices. Ms. Duraibabu currently serves as principal financial officer and principal accounting officer of the Company. For purposes of business continuity, effective as of the Transition Date, Ms. Duraibabu will transition to part-time employment with the Company, following which she will continue to serve as the Company's principal financial officer on an interim basis pending the appointment of a successor. The Company thanks Ms. Duraibabu for her significant contributions as Chief Financial Officer, including her key role in our strategic collaborations and investment allocations that have positioned the Company for its future as a neurology-focused genomic medicines company.
Sangamo Therapeutics Inc. published this content on September 11, 2025, and is solely responsible for the information contained herein. Distributed via SEC EDGAR on September 11, 2025 at 21:01 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]